Castle Biosciences president and CEO Derek Maetzold sells $515k stock

Derek J. Maetzold, President and Chief Executive Officer and a Director at Castle Biosciences Inc. (NASDAQ:CSTL), sold a total of 14,496 shares of the company’s common stock on October 5, 2026, for a total value of $515,564. The shares were sold at prices ranging from $35.310 to $35.965, with a weighted-average sale price of $35.566. These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Maetzold on June 2, 2026. The sale comes after Castle Biosciences shares delivered strong returns of nearly 49% over the past six months, according to InvestingPro data. The stock currently trades above its Fair Value, suggesting limited near-term upside. InvestingPro offers exclusive insights on CSTL, including additional ProTips and comprehensive financial metrics.

The sales included 8,580 shares held directly by Mr. Maetzold, 3,198 shares held indirectly by The Maetzold Descendants 2020 Trust, and 2,718 shares held indirectly by the Derek Maetzold 2020 Irrevocable Trust.

On the same date, Mr. Maetzold also acquired 8,165 shares of common stock through the exercise of a stock option at a price of $2.39 per share, totaling $19,514. The option was fully vested.

Following these transactions, Mr. Maetzold directly holds 21,064 shares of common stock. His indirect holdings include 8,038 shares through The Maetzold Descendants 2020 Trust, 6,832 shares through the Derek Maetzold 2020 Irrevocable Trust, and various other trusts. These include 11,256 shares each through The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, Hannah Elizabeth Maetzold, John Derek Maetzold, and Peter Douglas Maetzold. Additional indirect holdings are 11,963 shares through DJM Grantor Retained Annuity Trust No. 6, 27,862 shares through DJM Grantor Retained Annuity Trust No. 7, 40,935 shares through DJM Grantor Retained Annuity Trust No. 8, and 23,216 shares through DJM Grantor Retained Annuity Trust No. 9.

In other recent news, Castle Biosciences reported second-quarter results that exceeded Wall Street expectations for both profit and revenue. The company announced an adjusted loss of 7 cents per share, surpassing analysts’ predictions of a 40-cent loss. Revenue reached $103.5 million, significantly above the projected $86.4 million. The strong performance was attributed to increased test demand, prompting the company to raise its full-year sales guidance. Additionally, BTIG raised its price target for Castle Biosciences from $40 to $44, maintaining a Buy rating. The firm’s decision was influenced by a 20% revenue beat, driven by a 20% growth in revenue. Notably, the TissueCypher franchise contributed to this growth, with volumes increasing by 63% year-over-year and 28% quarter-over-quarter. These developments reflect a period of robust financial performance for Castle Biosciences.